Research Analysts Issue Forecasts for XENE Q1 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Xenon Pharmaceuticals in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will earn ($0.97) per share for the quarter. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ Q4 2025 earnings at ($1.23) EPS and FY2029 earnings at $2.05 EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05.

Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. Needham & Company LLC restated a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective on the stock. Finally, William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $57.38.

Xenon Pharmaceuticals Stock Up 0.6 %

XENE stock opened at $36.02 on Monday. The stock has a market capitalization of $2.76 billion, a P/E ratio of -12.77 and a beta of 1.26. The firm has a 50-day simple moving average of $39.17 and a 200-day simple moving average of $40.30. Xenon Pharmaceuticals has a 52 week low of $33.27 and a 52 week high of $47.44.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in XENE. Mirae Asset Global Investments Co. Ltd. increased its holdings in Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 487 shares in the last quarter. abrdn plc grew its holdings in shares of Xenon Pharmaceuticals by 16.9% during the third quarter. abrdn plc now owns 248,311 shares of the biopharmaceutical company’s stock worth $9,776,000 after buying an additional 35,809 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in Xenon Pharmaceuticals by 99.3% in the third quarter. Harbor Capital Advisors Inc. now owns 48,063 shares of the biopharmaceutical company’s stock valued at $1,892,000 after purchasing an additional 23,947 shares during the period. Assetmark Inc. grew its holdings in Xenon Pharmaceuticals by 7.9% in the third quarter. Assetmark Inc. now owns 19,670 shares of the biopharmaceutical company’s stock valued at $774,000 after purchasing an additional 1,435 shares during the period. Finally, TimesSquare Capital Management LLC grew its holdings in Xenon Pharmaceuticals by 3.2% in the third quarter. TimesSquare Capital Management LLC now owns 778,293 shares of the biopharmaceutical company’s stock valued at $30,641,000 after purchasing an additional 23,800 shares during the period. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian Mortimer sold 16,315 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now owns 31,302 shares of the company’s stock, valued at $1,267,731. This trade represents a 34.26 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,492 shares of company stock valued at $2,334,969. Insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.